Chapter: Fluid Resuscitation Volume and Vasopressor Timing in Shock

1. Assess clinical markers that guide fluid resuscitation and vasopressor initiation in shock.
2. Evaluate patient response to fluid resuscitation and devise a stewardship plan for patient fluid resuscitation.
3. Account for the limitations of the Surviving Sepsis Campaign guidelines in relation to vasopressor therapy initiation.
4. Develop a plan for the initiation of vasopressor therapy on the basis of patient-specific parameters.
5. Justify the role of critical care pharmacists in fluid stewardship and vasopressor initiation in shock. 

Chapter: Selecting Vasopressors in Septic Shock

1. Evaluate the mechanisms and consequences of hypotension in septic shock.
2. Distinguish the pharmacologic targets and adverse effects of various vasopressors.
3. Assess different phenotypes of vasopressor responsiveness.
4. Design a plan for applying vasopressors to a patient with septic shock. 

Chapter: Severe Musculoskeletal and Spinal Injuries

1. Evaluate patients for potential etiologies of musculoskeletal injuries and corresponding principles of management.
2. Apply principles demonstrating the pharmacist’s role in the prevention and treatment of medication-associated musculoskeletal injury.
3. Develop a treatment plan for the acute management of musculoskeletal injuries during the pre-hospital, ED, postoperative, and ICU phases of care.
4. Design appropriate treatment modalities for patients with spinal cord injury, compartment syndrome, and rhabdomyolysis.
5. Design supportive care of a critically ill patient with musculoskeletal injuries including infection prevention and treatment, pain control, and venous thromboembolism prophylaxis. 

Chapter: Immunomodulation in Critical Illness

1. Evaluate the role of the immune system in critical illness and approach to immunologic monitoring in the ICU
2. Apply the key physiologic alterations underlying the dysregulated immune response in critical illness and its associated consequences
3. Account for the impact of commonly used therapies in the ICU on the immune system
4. Evaluate the evidence surrounding the use of immunomodulatory agents in critical illness
5. Analyze the current literature evaluating alternative therapies for immune modulation in the ICU 

Chapter: Developing and Advancing Critical Care Pharmacy Practice Models

1. Justify the role of critical care pharmacists on the multiprofessional care team.
2. Apply management fundamentals, organizational psychology tenets, and ICU best practices.
3. Design strategies to develop and optimize pharmacotherapeutic care for critically ill patients.
4. Develop strategies for expanding practice involvement across the spectrum of institutional practice sites. 

Case Series: Critical Care Pharmacist Precepting, Mentoring, and Training

1. Compare and contrast use of the four preceptor roles in critical care practice.
2. Develop mentorship strategies for lifelong learning and development.
3. Design a training program for a critical care pharmacist. 

Chapter: Medication Safety and Technology in the ICU

1. Justify the role of the medication safety officer to improve the care of ICU patients.
2. Analyze available quality improvement tools and apply them to improve safe medication use in the ICU.
3. Demonstrate how to improve the safe use of medications for patients transitioning out of the ICU.
4. Evaluate the technology available to use in the ICU to promote safety and optimize care for critically ill patients.
5. Apply simulation-based activities and artificial intelligence to improve the care of ICU patients. 

Case Series: Pharmacy Services in the Telehealth ICU

1. Distinguish between traditional bedside critical care services and those provided by telehealth and telecritical care (TCC).
2. Evaluate the evidence supporting TCC pharmacist services.
3.  Design strategies to optimize cost savings in TCC pharmacy.
4. Assess existing legal and operational recommendations for telehealth pharmacy practice.

Case Series: Managing Drug Shortages and Providing Cost-Effective Pharmacotherapy

1. Account for the epidemiology of drug shortages affecting the critically ill population.
2. Identify how cost-effectiveness is applied to pharmacotherapy decision-making.
3. Evaluate the interplay between drug shortages and cost-effective pharmacotherapy in the critically ill population.
4. Design a strategy, including both operational and clinical considerations, to optimize the management of drug shortages in the critically ill population.